Welcome to our dedicated page for Medifast news (Ticker: MED), a resource for investors and traders seeking the latest updates and insights on Medifast stock.
Medifast Inc (MED) provides investors and stakeholders with centralized access to official company announcements and market-moving developments. This resource aggregates all press releases, financial disclosures, and strategic updates from the clinical nutrition leader known for its OPTAVIA® coaching programs and evidence-based weight management solutions.
Users will find chronological updates covering earnings reports, product innovations, leadership changes, and operational milestones. The curated collection serves as both historical record and strategic tool for tracking MED's position in the $250B+ global wellness industry.
Key content categories include quarterly financial results, clinical study publications, partnership announcements, and regulatory filings. All materials are sourced directly from Medifast's investor relations team to ensure accuracy and timeliness.
Bookmark this page for streamlined monitoring of MED's business trajectory, with updates organized to highlight material developments affecting long-term growth in the health solutions sector.
Medifast (NYSE: MED) reported Q2 2024 financial results, showing a 43.1% decrease in revenue to $168.6 million. The company experienced a net loss of $8.2 million, or $0.75 per diluted share. Key metrics include:
- Revenue per active earning Coach: $4,972
- Independent active earning OPTAVIA Coaches: 33,900
- Non-GAAP adjusted net income: $10.1 million
- Non-GAAP adjusted EPS: $0.92
- Cash and equivalents: $163.5 million with zero debt
Medifast is transforming its business for long-term growth, focusing on new customer acquisition and expanding its health and wellness offerings. The company's outlook for Q3 2024 projects revenue between $125-$145 million and a diluted loss per share of $0.05 to $0.70.
Medifast (NYSE: MED), the health and wellness company behind the OPTAVIA® lifestyle solution, has announced it will release its second quarter 2024 financial results on Monday, August 5, 2024, after market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results, featuring Dan Chard, Chairman and CEO, and Jim Maloney, CFO.
The call will be broadcast live on Medifast's Investor Relations website and archived until November 5, 2024. Listeners can join via telephone by dialing (201) 389-0879. A telephonic playback will be available from 8:30 p.m. ET, August 5, through August 12, 2024, accessible by dialing (412) 317-6671 with access code 13747501.
Medifast (NYSE: MED), a health and wellness company, has been recognized as one of the 'Best Companies to Work For' in the food and drink industry for 2024-2025 by U.S. News & World Report. This marks the second consecutive year Medifast has received this distinction, highlighting its focus on creating a positive workplace culture. CEO Dan Chard credits the company's transformation to the dedication and resilience of its employees. The ranking, determined by a panel of experts, evaluates companies based on six factors important to employee well-being, including pay, benefits, work-life balance, and career opportunities. Medifast's OPTAVIA® program continues to drive its mission of promoting a healthy lifestyle.
Medifast (NYSE: MED) has launched a national marketing campaign worth up to $30 million to promote its new GLP-1 Lifestyle Program, in collaboration with LifeMD. This program integrates clinician-prescribed medications, coach support, and a new GLP-1 Nutrition Support Kit. The campaign aims to drive customer acquisition and increase brand visibility. It includes new branding, visuals, and an enhanced digital presence. The GLP-1 Nutrition Support Kit, priced at $217.15/month via auto-ship, includes high-protein products designed to support weight management. Medifast's strategy focuses on marketing initiatives, coach network expansion, and strategic collaborations to drive growth.
Medifast reported first quarter 2024 financial results with revenue of $174.7 million, net income of $8.3 million, and EPS of $0.76. The company highlighted a transformative approach to weight loss solutions, targeting a potential $50B market. However, revenue decreased by 49.9% primarily due to lower Coach productivity and active earning OPTAVIA Coaches. Gross profit decreased by 48.3%, while selling, general, and administrative expenses decreased by 38.1%. Income from operations decreased by 85.2% to $7.9 million. The company's balance sheet remained strong with $156.4 million in cash and no debt. The outlook for the second quarter 2024 includes revenue between $150 million to $170 million and diluted EPS between $0.05 to $0.40.
FAQ
What is the current stock price of Medifast (MED)?
What is the market cap of Medifast (MED)?
